SG172889A1 - Compositions and methods for assessing cytotoxicity of single cells - Google Patents
Compositions and methods for assessing cytotoxicity of single cells Download PDFInfo
- Publication number
- SG172889A1 SG172889A1 SG2011049459A SG2011049459A SG172889A1 SG 172889 A1 SG172889 A1 SG 172889A1 SG 2011049459 A SG2011049459 A SG 2011049459A SG 2011049459 A SG2011049459 A SG 2011049459A SG 172889 A1 SG172889 A1 SG 172889A1
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- cell
- microwell
- hiv
- effector
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 123
- 231100000135 cytotoxicity Toxicity 0.000 title claims description 11
- 230000003013 cytotoxicity Effects 0.000 title claims description 10
- 239000000203 mixture Substances 0.000 title description 5
- 239000012636 effector Substances 0.000 claims abstract description 93
- 210000004027 cell Anatomy 0.000 claims description 283
- 210000000822 natural killer cell Anatomy 0.000 claims description 103
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 96
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 50
- 239000000758 substrate Substances 0.000 claims description 43
- 102000004127 Cytokines Human genes 0.000 claims description 40
- 108090000695 Cytokines Proteins 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 38
- 230000009089 cytolysis Effects 0.000 claims description 35
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 29
- 238000001514 detection method Methods 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 208000031886 HIV Infections Diseases 0.000 claims description 21
- 239000000725 suspension Substances 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 210000002845 virion Anatomy 0.000 claims description 18
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 17
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 12
- 108010029697 CD40 Ligand Proteins 0.000 claims description 11
- 102100032937 CD40 ligand Human genes 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 11
- 238000000151 deposition Methods 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 8
- 102000001398 Granzyme Human genes 0.000 claims description 7
- 108060005986 Granzyme Proteins 0.000 claims description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 230000015788 innate immune response Effects 0.000 claims description 7
- 239000006166 lysate Substances 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 229930192851 perforin Natural products 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 6
- 230000005875 antibody response Effects 0.000 claims description 6
- 239000000975 dye Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 238000011225 antiretroviral therapy Methods 0.000 claims description 4
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 102100033467 L-selectin Human genes 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical group COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 230000009260 cross reactivity Effects 0.000 claims description 2
- 238000012052 concurrent chemoradiation therapy Methods 0.000 claims 1
- 238000002493 microarray Methods 0.000 abstract description 15
- 230000003993 interaction Effects 0.000 abstract description 8
- 238000013537 high throughput screening Methods 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 56
- 238000003556 assay Methods 0.000 description 46
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 21
- 230000001461 cytolytic effect Effects 0.000 description 19
- 238000013459 approach Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 230000004044 response Effects 0.000 description 13
- 238000003491 array Methods 0.000 description 12
- 230000002147 killing effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 108010043610 KIR Receptors Proteins 0.000 description 8
- 102000002698 KIR Receptors Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000002101 lytic effect Effects 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 102000004503 Perforin Human genes 0.000 description 6
- 108010056995 Perforin Proteins 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 229940033330 HIV vaccine Drugs 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 5
- 241000713311 Simian immunodeficiency virus Species 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000012252 genetic analysis Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229960002378 oftasceine Drugs 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940124718 AIDS vaccine Drugs 0.000 description 3
- 206010000807 Acute HIV infection Diseases 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 108091008877 NK cell receptors Proteins 0.000 description 3
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000012203 high throughput assay Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- -1 polydimethylsiloxane Polymers 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000006390 HLA-B Antigens Human genes 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 2
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 2
- 101000945492 Homo sapiens Killer cell immunoglobulin-like receptor 3DS1 Proteins 0.000 description 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 2
- 102100034833 Killer cell immunoglobulin-like receptor 3DS1 Human genes 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011266 cytolytic assay Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000000428 immunological synapse Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- RJPSHDMGSVVHFA-UHFFFAOYSA-N 2-[carboxymethyl-[(7-hydroxy-4-methyl-2-oxochromen-8-yl)methyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C=CC2=C1OC(=O)C=C2C RJPSHDMGSVVHFA-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000812 repeated exposure Toxicity 0.000 description 1
- 238000000820 replica moulding Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14610609P | 2009-01-21 | 2009-01-21 | |
| PCT/US2009/050411 WO2010085275A1 (en) | 2009-01-21 | 2009-07-13 | Compositions and methods for assessing cytotoxicity of single cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG172889A1 true SG172889A1 (en) | 2011-08-29 |
Family
ID=42356144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201401643PA SG10201401643PA (en) | 2009-01-21 | 2009-07-13 | Methods for assessing cytotoxicity of single cells |
| SG2011049459A SG172889A1 (en) | 2009-01-21 | 2009-07-13 | Compositions and methods for assessing cytotoxicity of single cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201401643PA SG10201401643PA (en) | 2009-01-21 | 2009-07-13 | Methods for assessing cytotoxicity of single cells |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9244071B2 (enExample) |
| EP (1) | EP2389446B1 (enExample) |
| JP (2) | JP2012515548A (enExample) |
| KR (1) | KR20110134386A (enExample) |
| CN (2) | CN104745669A (enExample) |
| AU (1) | AU2009338127B2 (enExample) |
| CA (1) | CA2689681C (enExample) |
| IL (1) | IL213938A0 (enExample) |
| RU (1) | RU2532228C2 (enExample) |
| SG (2) | SG10201401643PA (enExample) |
| WO (1) | WO2010085275A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102308213B (zh) | 2008-12-04 | 2014-10-29 | 麻省理工学院 | 诊断过敏性反应的方法 |
| US9404924B2 (en) | 2008-12-04 | 2016-08-02 | Massachusetts Institute Of Technology | Method of performing one-step, single cell RT-PCR |
| CA2689681C (en) | 2009-01-21 | 2017-08-29 | Massachusetts Institute Of Technology | Compositions and methods for assessing cytotoxicity of single cells |
| WO2012072823A1 (en) * | 2010-12-03 | 2012-06-07 | Mindseeds Laboratories Srl | Rapid screening of monoclonal antibodies |
| EP3035031B1 (en) | 2010-12-03 | 2022-06-01 | Cellply S.R.L. | Microanalysis of cellular function |
| EP2791358B1 (en) * | 2011-12-13 | 2017-06-14 | Single Cell Technology, Inc. | Method of screening a plurality of single secreting cells for functional activity |
| US20150191772A1 (en) | 2012-06-29 | 2015-07-09 | Danmarks Tekniske Universitet | Method of charging a test carrier and a test carrier |
| JP6197039B2 (ja) * | 2012-08-24 | 2017-09-13 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | ハイスループット多重検出用システム、装置及び方法 |
| EP3039162B1 (en) * | 2013-08-26 | 2019-01-02 | President and Fellows of Harvard College | Determination of immune cells and other cells |
| US9877486B2 (en) | 2014-01-31 | 2018-01-30 | AgBiome, Inc. | Methods of growing plants using modified biological control agents |
| HRP20211763T1 (hr) | 2014-01-31 | 2022-02-18 | AgBiome, Inc. | Modificirano sredstvo za biološku kontrolu i njegove primjene |
| WO2016090148A1 (en) | 2014-12-03 | 2016-06-09 | IsoPlexis Corporation | Analysis and screening of cell secretion profiles |
| US10488321B2 (en) | 2015-03-19 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Devices and methods for high-throughput single cell and biomolecule analysis and retrieval in a microfluidic chip |
| EP3274720B1 (en) | 2015-03-26 | 2023-12-27 | University of Houston System | Integrated functional and molecular profiling of cells |
| EP3402902B1 (en) | 2016-01-15 | 2021-10-27 | Massachusetts Institute Of Technology | Semi-permeable arrays for analyzing biological systems and methods of using same |
| WO2017165791A1 (en) | 2016-03-25 | 2017-09-28 | President And Fellows Of Harvard College | Microfluidic determination of immune and other cells |
| US20190106666A1 (en) * | 2016-03-30 | 2019-04-11 | Sony Corporation | Cell observation device, method for evaluating activity level of immune cells, and method for controlling quality of immune cells |
| EP3469376B1 (en) | 2016-06-14 | 2023-09-06 | Cellply S.R.L. | Screening method |
| CN109563539A (zh) | 2016-06-15 | 2019-04-02 | 慕尼黑路德维希马克西米利安斯大学 | 使用dna纳米技术的单分子检测或定量 |
| CN106086171A (zh) * | 2016-06-15 | 2016-11-09 | 广州中大南沙科技创新产业园有限公司 | 一种抑制肿瘤细胞增殖的药物筛选方法 |
| WO2018049418A1 (en) | 2016-09-12 | 2018-03-15 | IsoPlexis Corporation | System and methods for multiplexed analysis of cellular and other immunotherapeutics |
| CN110168069A (zh) * | 2016-10-19 | 2019-08-23 | 通用自动化实验技术公司 | 用于筛选微生物和其他高通量微生物学应用的高分辨率系统、试剂盒、设备和方法 |
| EP4036578A1 (en) * | 2016-11-11 | 2022-08-03 | Isoplexis Corporation | Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells |
| US11085912B2 (en) * | 2016-12-14 | 2021-08-10 | University Of Cincinnati | Methods of diagnosing Clostridium difficile infection or recurrence in a subject |
| SE543211C2 (en) | 2017-06-29 | 2020-10-27 | Mabtech Production Ab | Method and system for analyzing Fluorospot assays |
| AU2018378827B2 (en) | 2017-12-07 | 2023-04-13 | Massachusetts Institute Of Technology | Single cell analyses |
| CN108728356B (zh) * | 2018-05-23 | 2022-02-22 | 北京科技大学 | 用于不同三维细胞团配对的装置及共培养方法 |
| CN113614532A (zh) * | 2019-01-16 | 2021-11-05 | 烟台澳斯邦生物工程有限公司 | 沉积用于显微镜检查的生物样品的自动液体处理系统和方法 |
| WO2020171020A1 (ja) * | 2019-02-18 | 2020-08-27 | 株式会社エヌビィー健康研究所 | 細胞の選抜方法、核酸の製造方法、組換え細胞の製造方法、目的物質の製造方法、医薬組成物の製造方法、及び試薬 |
| US12064768B2 (en) | 2020-02-21 | 2024-08-20 | Northeastern University | Single cell isolation and processing system with reversible well shape |
| CN120693393A (zh) | 2022-11-07 | 2025-09-23 | 神农生物技术公司 | 用于高通量筛选细胞间相互作用的微流体装置 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68507A (en) | 1982-05-10 | 1986-01-31 | Univ Bar Ilan | System and methods for cell selection |
| SU1650094A1 (ru) * | 1987-12-29 | 1991-05-23 | Научно-исследовательский институт проктологии | Способ диагностики прот женности активного воспалени в толстой кишке при неспецифическом звенном колите |
| US6410252B1 (en) | 1995-12-22 | 2002-06-25 | Case Western Reserve University | Methods for measuring T cell cytokines |
| US6210910B1 (en) | 1998-03-02 | 2001-04-03 | Trustees Of Tufts College | Optical fiber biosensor array comprising cell populations confined to microcavities |
| WO2000061629A1 (en) * | 1999-04-09 | 2000-10-19 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| JP2003502062A (ja) * | 1999-06-11 | 2003-01-21 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４９個のヒト分泌タンパク質 |
| US7332286B2 (en) * | 2001-02-02 | 2008-02-19 | University Of Pennsylvania | Peptide or protein microassay method and apparatus |
| US20020141906A1 (en) | 2001-03-30 | 2002-10-03 | American Type Culture Collection | Microtiter plate sealing cover with well identifiers |
| US7776553B2 (en) | 2005-09-16 | 2010-08-17 | Presidents And Fellows Of Harvard College | Screening assays and methods |
| US20110124520A1 (en) | 2008-05-30 | 2011-05-26 | Massachuesetts Institute Of Technology | Compositions and Methods for Spatial Separation and Screening of Cells |
| US9404924B2 (en) | 2008-12-04 | 2016-08-02 | Massachusetts Institute Of Technology | Method of performing one-step, single cell RT-PCR |
| CN102308213B (zh) | 2008-12-04 | 2014-10-29 | 麻省理工学院 | 诊断过敏性反应的方法 |
| CA2689681C (en) | 2009-01-21 | 2017-08-29 | Massachusetts Institute Of Technology | Compositions and methods for assessing cytotoxicity of single cells |
| US8569046B2 (en) | 2009-02-20 | 2013-10-29 | Massachusetts Institute Of Technology | Microarray with microchannels |
-
2009
- 2009-07-13 CA CA2689681A patent/CA2689681C/en not_active Expired - Fee Related
- 2009-07-13 AU AU2009338127A patent/AU2009338127B2/en not_active Ceased
- 2009-07-13 KR KR1020117018895A patent/KR20110134386A/ko not_active Ceased
- 2009-07-13 US US13/145,300 patent/US9244071B2/en active Active
- 2009-07-13 WO PCT/US2009/050411 patent/WO2010085275A1/en not_active Ceased
- 2009-07-13 SG SG10201401643PA patent/SG10201401643PA/en unknown
- 2009-07-13 CN CN201510140107.0A patent/CN104745669A/zh active Pending
- 2009-07-13 CN CN2009801551526A patent/CN102388145A/zh active Pending
- 2009-07-13 EP EP09839012.3A patent/EP2389446B1/en not_active Not-in-force
- 2009-07-13 SG SG2011049459A patent/SG172889A1/en unknown
- 2009-07-13 RU RU2011134898/10A patent/RU2532228C2/ru not_active IP Right Cessation
- 2009-07-13 JP JP2011547913A patent/JP2012515548A/ja not_active Withdrawn
-
2011
- 2011-07-05 IL IL213938A patent/IL213938A0/en unknown
-
2015
- 2015-05-05 JP JP2015094509A patent/JP6017620B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2389446B1 (en) | 2017-07-05 |
| WO2010085275A1 (en) | 2010-07-29 |
| CA2689681C (en) | 2017-08-29 |
| US9244071B2 (en) | 2016-01-26 |
| RU2011134898A (ru) | 2013-02-27 |
| RU2532228C2 (ru) | 2014-10-27 |
| CN104745669A (zh) | 2015-07-01 |
| EP2389446A4 (en) | 2012-10-03 |
| JP2012515548A (ja) | 2012-07-12 |
| AU2009338127A1 (en) | 2011-07-28 |
| CA2689681A1 (en) | 2010-07-21 |
| AU2009338127B2 (en) | 2015-11-26 |
| EP2389446A1 (en) | 2011-11-30 |
| JP6017620B2 (ja) | 2016-11-02 |
| JP2015144617A (ja) | 2015-08-13 |
| CN102388145A (zh) | 2012-03-21 |
| IL213938A0 (en) | 2011-07-31 |
| KR20110134386A (ko) | 2011-12-14 |
| SG10201401643PA (en) | 2014-08-28 |
| US20120149592A1 (en) | 2012-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9244071B2 (en) | Compositions and methods for assessing cytotoxicity of single cells | |
| Clute et al. | Cross-reactive influenza virus–specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus–associated infectious mononucleosis | |
| US8975069B2 (en) | Method for identifying antigen-specific regulatory T cells | |
| Wullner et al. | Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics | |
| US20210102942A1 (en) | High-throughput method to screen cognate T cell and epitope reactivities in primary human cells | |
| Heutinck et al. | Virus-specific CD8+ T cells cross-reactive to donor-alloantigen are transiently present in the circulation of kidney transplant recipients infected with CMV and/or EBV | |
| JP2015144617A5 (enExample) | ||
| Homann et al. | Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity | |
| Borchers et al. | Multimer monitoring of CMV-specific T cells in research and in clinical applications | |
| Tørring et al. | Higher incidence of Epstein–Barr virus‐induced lymphocyte transformation in multiple sclerosis | |
| CA2968543A1 (en) | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing | |
| Nyanhete et al. | HLA class II-restricted CD8+ T cells in HIV-1 virus controllers | |
| Mahlobo et al. | The impact of HIV infection on the frequencies, function, spatial localization and heterogeneity of T follicular regulatory cells (TFRs) within human lymph nodes | |
| Abu‐Khader et al. | Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation‐a comparison of different assays for the detection of cytomegalovirus‐specific T cells | |
| Cohen et al. | Isolation of viable antigen-specific CD4 T cells by CD40L surface trapping | |
| Koo et al. | Defining T cell receptor repertoires using nanovial-based affinity and functional screening | |
| Bousso et al. | A clonal view of αβ T cell responses | |
| US20080051297A1 (en) | Method for determining antigen-specific T cell response in high throughput format | |
| Richard | Toll-like receptor (TLR) 7 and TLR8 stimulation of mucosal-associated invariant T cells and gamma delta T cells: a role in HIV susceptibility | |
| James | Molecular and Cellular Mechanisms of Mycobacterial Glycolipid Recognition by Human T Cells | |
| Razmi | Killer Cell Immunoglobulin-Like Receptors Delineate Distinct Phenotypes and Functions in Human γδ T Cells | |
| Williams | Role of TCR affinity in function, proliferation, memory generation, and exhaustion during human viral infection | |
| Catry | Specific T-and B-cell responses against Human cytomegalovirus after Hematopoietic stem cell transplantation | |
| Robertson | Development of MHC class I African alleles and ex vivo detection of M. tuberculosis-reactive CD8+ T-cells | |
| Brock et al. | Role of TCR affinity in function, proliferation, memory generation, and exhaustion during human viral infection |